Long-Acting Muscarinic Antagonists for Difficult-to-Treat Asthma: Emerging Evidence and Future Directions

被引:4
|
作者
Bulkhi, Adeeb [1 ,2 ]
Tabatabaian, Farnaz [1 ]
Casale, Thomas B. [1 ]
机构
[1] Univ S Florida, Dept Internal Med, Div Allergy & Immunol, 12901 Bruce B Downs Blvd,MDC 19, Tampa, FL 33612 USA
[2] Umm Al Qura Univ, Coll Med, Dept Internal Med, Mecca, Saudi Arabia
基金
美国国家卫生研究院;
关键词
OBSTRUCTIVE PULMONARY-DISEASE; TIOTROPIUM BROMIDE; ADULT PATIENTS; INHALED CORTICOSTEROIDS; AIRWAY INFLAMMATION; ACLIDINIUM BROMIDE; UMECLIDINIUM; RESPIMAT(R); RECEPTORS; THERAPY;
D O I
10.1007/s40265-016-0599-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Asthma is a complex disease where many patients remain symptomatic despite guideline-directed therapy. This suggests an unmet need for alternative treatment approaches. Understanding the physiological role of muscarinic receptors and the parasympathetic nervous system in the respiratory tract will provide a foundation of alternative therapeutics in asthma. Currently, several long-acting muscarinic antagonists (LAMAs) are on the market for the treatment of respiratory diseases. Many studies have shown the effectiveness of tiotropium, a LAMA, as add-on therapy in uncontrolled asthma. These studies led to FDA approval for tiotropium use in asthma. In this review, we discuss how the neurotransmitter acetylcholine itself contributes to inflammation, bronchoconstriction, and remodeling in asthma. We further describe the current clinical studies evaluating LAMAs in adult and adolescent patients with asthma, providing a comprehensive review of the current known physiological benefits of LAMAs in respiratory disease.
引用
收藏
页码:999 / 1013
页数:15
相关论文
共 50 条
  • [31] Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases
    Alagha, Khuder
    Palot, Alain
    Sofalvi, Tunde
    Pahus, Laurie
    Gouitaa, Marion
    Tummino, Celine
    Martinez, Stephanie
    Charpin, Denis
    Bourdin, Arnaud
    Chanez, Pascal
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2014, 5 (02) : 85 - 98
  • [32] Inhaled long-acting muscarinic antagonists in chronic obstructive pulmonary disease
    Busch-Petersen, Jakob
    Laine, Dramane I.
    FUTURE MEDICINAL CHEMISTRY, 2011, 3 (13) : 1623 - 1634
  • [33] Association Between Recent and Future Asthma Exacerbations in Pediatric Patients With Severe or Difficult-to-Treat Asthma
    Fish, J. E.
    Haselkorn, T.
    Mink, D. R.
    Massanari, M.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (02) : S161 - S161
  • [34] Optimal Bronchodilation for COPD Patients: Are All Long-Acting beta(2)-Agonist/Long-Acting Muscarinic Antagonists the Same?
    Miravitlles, Marc
    Baek, Seungjae
    Vithlani, Vatsal
    Lad, Rahul
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2018, 81 (03) : 198 - 215
  • [35] Genetics, Ethics, and the Use of Long-acting β-Adrenergics to Treat Asthma
    Martinez, Fernando D.
    Fabbri, Leonardo M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181 (07) : 647 - 648
  • [36] Biomarkers to Predict Response to Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists in Adolescents and Adults with Mild Persistent Asthma
    Krishnan, Jerry A.
    Lazarus, Stephen C.
    Blake, Kathryn, V
    Sorkness, Christine A.
    Covar, Ronina
    Dyer, Anne-Marie
    Lang, Jason E.
    Lugogo, Njira L.
    Mauger, David T.
    Wechsler, Michael E.
    Wenzel, Sally E.
    Cardet, Juan Carlos
    Castro, Mario
    Israel, Elliot
    Phipatanakul, Wanda
    King, Tonya S.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2022, 19 (03) : 372 - 380
  • [37] Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium
    Hamelmann, Eckard
    BIOMED RESEARCH INTERNATIONAL, 2018, 2018
  • [38] The use of a long-acting muscarinic antagonist in the treatment of asthma: A tertiary asthma center experience
    Ozturk, Betul Ozdel
    Sozener, Zeynep Celebi
    Metan, Esra Unsay
    Aydin, Omur
    Bavbek, Sevim
    Mungan, Dilsad
    ALLERGOLOGIA ET IMMUNOPATHOLOGIA, 2024, 52 (06) : 62 - 71
  • [39] Long-Acting β-Agonists (LABA) Combined With Long-Acting Muscarinic Antagonists or LABA Combined With Inhaled Corticosteroids for Patients With Stable COPD
    Horita, Nobuyuki
    Nagashima, Akimichi
    Kaneko, Takeshi
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (13): : 1274 - 1275
  • [40] 2020 Updated Asthma Guidelines: Intermittent inhaled corticosteroids and long-acting muscarinic antagonists for asthma-the latest NAEPP guidelines are SMART!
    Wechsler, Michael E.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (05) : 1640 - 1642